This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
by Zacks Equity Research
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
TGTXNegative Net Change LQDANegative Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
by Sundeep Ganoria
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
BMYNegative Net Change MRKPositive Net Change AGENNegative Net Change IOVAPositive Net Change
biotechs cell-therapy medical pharmaceuticals
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use
by Zacks Equity Research
Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.
AZNNegative Net Change IRWDNegative Net Change ABBVPositive Net Change
biotechs
AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication
by Zacks Equity Research
ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.
ABBVPositive Net Change LQDANegative Net Change IMCRPositive Net Change INDVNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
by Ekta Bagri
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
ADMANegative Net Change NTLANegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts
by Zacks Equity Research
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
SNYNegative Net Change BMYNegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
by Zacks Equity Research
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
AZNNegative Net Change PFENegative Net Change MRKPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
by Ahan Chakraborty
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
by Ahan Chakraborty
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
by Ahan Chakraborty
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals